Keith Speights

Keith Speights


Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.

Recent articles

2020 through 2025 painted on road

Where Will Gilead Sciences Be in 5 Years?

Some things are easy to predict for the big biotech. Others aren't.

Drawing of brain with brain wave lines

Why Marinus Pharmaceuticals Stock Skyrocketed 80% Higher Today

Investors are thrilled with the results from a late-stage clinical study of the company's only pipeline drug candidate.

Woman drawing big yellow fish about to eat small yellow fish

Should You Buy Gilead Now That It's Acquiring Immunomedics?

It's going to be a while before we know if Gilead's $21 billion deal will pay off.

Businessman with arrows pointing up and viruses

These 3 Coronavirus Stocks Could More Than Double by the End of 2020

Each of these biotech stocks has more than tripled year to date and could still have plenty of room to run.

Syringe, globe, currency symbols

How Novavax Is Keeping Up With the Big Players in the Coronavirus Vaccine Race

This small biotech could be the biggest winner of all if its COVID-19 vaccine performs well in late-stage testing.

Doctor reviewing brain MRI scans

Why Ziopharm Oncology Shares Zoomed Higher Today

One of the biotech's pipeline candidates won a key FDA designation.

Scientist looking through microscope

Why VBI Vaccines Stock Jumped Today

The biotech will present additional data for one of its pipeline candidates later this week.

Green light arrow

Why Vaxart Stock Is Crushing It Today

The FDA gave a green light for the biotech to begin phase 1 testing of its coronavirus vaccine candidate.

Doctor holding COVID-19 vaccine with thumb up

The Surefire Vaccine Winner Following AstraZeneca's COVID-19 Trial Pause

Hint: It's not Moderna.

Cannabis plants with hydroponics

Could GrowGeneration Be a Millionaire-Maker Stock?

Maybe. Here's how it could happen.

$100 bills forming infinity symbol

3 Rock-Solid Dividend Stocks That You Can Buy and Hold Forever

No worries needed with these stable dividend stars.

Hand picking up COVID-19 vaccine bottle

Coronavirus Vaccine Race: 7 Key Things You'll Want to Know

Here are the answers to your top questions about where things stand with the development of COVID-19 vaccines.

Dollar sign with coronavirus

Better Coronavirus Stock: Altimmune or Vaxart?

These biotechs are developing coronavirus vaccines with a twist.

2 scientists in lab

Why Spero Therapeutics Shares Are Sliding Today

The pricing of a stock offering is causing the drugmaker's shares to fall.

Arrows pointing down with one pointing up

3 Incredibly Strong Stocks to Buy That Should Thrive Even If the Stock Market Crashes Again

These rock-solid businesses should be resilient no matter what happens with the stock market or the economy.

Businessman looking at red line going through floor

Why Satsuma Pharmaceuticals Stock Is Plummeting Today

Investors are reeling from a late-stage flop for the company's only pipeline candidate.

Businessman pointing to sell

What to Know About Moderna's Insider Selling

An overview of who's selling, why, and whether to worry.

Injecting COVID-19 vaccine into globe

3 Compelling Reasons to Buy Novavax Right Now

This clinical-stage biotech stock appears to be an attractive pick for aggressive investors after its recent pullback.

Roll of $100 bills

Where to Invest $5,000 Right Now

Put your money in these three leaders in e-commerce, healthcare, and digital payments.

Coronavirus vaccine bottles

Pfizer's Latest Stealthy Move Could Help It Win the Coronavirus Vaccine Race

The big drugmaker is taking a quiet but smart step with its COVID-19 vaccine program.